Antoine Italiano
University of Bordeaux
528 Papers
1.1K Citations
Antoine Italiano is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 56, co-authored 366 publications. Previous affiliations of Antoine Italiano include Argonne National Laboratory & French Institute of Health and Medical Research.
Chat about Author
Papers
Prognostic or Predictive? It's Time to Get Back to Definitions!
TL;DR: The authors claimed in the Discussion section that their results “revealed a strong predictive value of Nuc-pYStat5 for response to antiestrogen therapy,” but the study design chosen by Peck et al 1 does not fit these criteria.
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
Sophie Cousin,Coralie Cantarel,Jean-Philippe Guégan,Thibault Mazard,Carlos Gomez-Roca,Jean-Philippe Metges,Carine Bellera,Antoine Adenis,Iphigenie Korakis,Pierre-Guillaume Poureau,Kevin Bourcier,Maud Toulmonde,Michèle Kind,Christophe Rey,Céline Auzanneau,Alban Bessede,Isabelle Soubeyran,Antoine Italiano +17 more
TL;DR: In this article , a single-arm, multicentric phase II trial was conducted to evaluate the effectiveness of Regorafenib and avelumab in patients with advanced biliary tract cancer.
Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer
Komal Jhaveri,Kevin Kalinsky,Philippe L. Bedard,Andrés Cervantes,Cristina Saura,Ian E. Krop,Erika Hamilton,Peter Schmid,Andrea Varga,Nicholas C. Turner,Antoine Italiano,Valentina Gambardella,Zachary William Neil Veitch,Mafalda Oliveira,Leslie J. Dickmann,Naoki Kotani,Amy V. Kapp,Katie Hutchinson,Stephanie Royer-Joo,Anjali Vaze,Jennifer L. Schutzman,Dejan Juric +21 more
TL;DR: Galone as mentioned in this paper is a p110α-selective, p110 α-mutant degrading inhibitor with anti-tumor activity in PIK3CAmutant breast cancer xenograft models.
Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.
Hyun Cheol Chung,Jan H.M. Schellens,Jean-Pierre Delord,Ruth Perets,Antoine Italiano,Ronnie Shapira-Frommer,Lyudmila Manzuk,Sarina Anne Piha-Paul,Jiangdian Wang,Susan Zeigenfuss,Scott K. Pruitt,Aurélien Marabelle +11 more
TL;DR: The KEYNOTE-158 study is a phase II basket study investigating the antitumor activity of pembrolizumab, an IgG4 anti-PD-1 monoclonal antibody, in 11 cancer types.